 (Can J Psychiatry 1999;44:991-998) 
treatment-are considered. The final section draws some conclusions about the course of future treatment research and the methodology of the MTA.
The MTA Study
The MTA study used a factorial design to evaluate 4 types of treatments for ADHD: 1) medication management, 2) intensive behavioural treatment, 3) combined treatment, and 4) community care treatment by community providers. Sponsored by NIMH, it was a cooperative venture including investigators from 6 sites. Subject enlistment began in 1994 and ended in 1998. Each site enrolled approximately 96 children aged 7-9 years (n = 579) randomly allocated (n~144 per group) to each condition. A multiple gating and assessment procedure was used to screen for eligibility, to establish willingness to comply with treatment protocols, and to obtain informed consent. Study assignment was randomized and revealed only after consent for participation was obtained. Treatment manuals were used with algorithms designed to achieve adequate response in medication use and to capitalize on potential synergies in combined treatment. Standard assessments covered multiple concepts (for example, symptomatology, social and academic functioning, and growth), incorporated multiple informants (for example, parents, teachers, and students), and used multiple methods (for example, problem checklists, classroom and videotape ratings by observers naive to subject treatment status, and standard achievement tests and sociometric ratings by student peers).
The first outcomes report covered 14 months, with assessments done at baseline and 3,9, and 14 months (7) . Random regression models and planned a priori comparisons between the treatment groups were used to characterize student changes over time transformed to a log scale. The study results indicate: 1) the superiority of medication management over behavioural treatment in reducing parent-and teacherreported symptoms ofADHD; 2) the superiority ofcombined treatment over behavioural treatment but not medication management in reducing parent-and teacher-reported symptoms of ADHD; 3) the superiority ofcombined treatment and medication management but not behavioural treatment over community care in reducing parent-and teacher-reported symptoms of ADHD; and 4) the superiority of combined treatment but neither medication management nor behavioural treatment over behavioural treatment in improving non-ADHD domains of functioning. One notable finding was the amount of improvement in the community care group. Measured as a standardized change score (amount of change divided by standard deviation of baseline) between baseline and 14 months, parent and teacher ratings of ADHD symptoms improved from 0.9 to 1.0 standard units, conventionally viewed as a large treatment effect (11) . Standardized effects for combined treatment and medication management on the same measures reached 1.5 to 1.8.
MTA Study-Methodological Achievements
The MTA study is a remarkable accomplishment. Multisite treatment studies are brand new to child mental health. The NIMH sponsors were able to harness the knowledge, experience, and energy ofprominent ADHD investigators in the US and focus them on a single enterprise-no small feat among committed, highly independent researchers. The cooperative effort gave way to a complex, standardized, carefully implemented, randomized control trial that meets most, if not all, standards ofmethodological quality, except for blinding (12) . This standard is most difficult to achieve in studies that involve psychosocial treatments: it is almost impossible to mask treatment allocations from subjects, investigators, and research staff responsible for data collection. Even in pharmacological trials in psychiatry, drug profiles are often distinctive, leading de facto to unmasking. Although the MTA study might have included placebo medication management with behavioural treatment and a placebo psychosocial experience with medication, it is unlikely that such strategies would have strengthened the trial. The investigators were well aware of the potential effects arising from treatment expectancies and rater bias. For this reason, complementary assessment methods (that is, classroom ratings by naive observers, sociometric ratings by peers, and parent-child interactions captured on videotape for later rating) were included to place in context assessments derived from parents and teachers involved in the trial interventions. From a methodological perspective, it is noteworthy that the MTA studyis characterized by almost perfect reporting (13) and insignificant sample attrition. The analyses were simple, elegant, and appropriate. In many ways, the design, conduct, and reporting ofthe MTA study set a benchmark oftechnical excellence for large-scale studies of its kind.
MTA Study-Methodological Issues
In designing a clinical trial, investigators often face difficult choices in specifying the research question, selecting endpoints, choosing subjects for study, packaging treatments, and controlling bias. Very often, these choices are buffetedby competing alternatives that facilitate, to varying degrees, the attainment ofoverall research objectives. In many studies,the right choices are not at all obvious; they are a matter of perspective and the subject of hot debate. Very often the consequences of certain choices are difficult to anticipate and may not become apparent until the study is underway or complete.
Given the technical excellence of the MTA study, the methodological issues drawing attention in this report centre on key decisions the investigators had to make in order to conduct the trial. In our view, these decisions have had direct and important influences on the magnitude of effects observed in the trial, both absolute and relative, and on the extent to which the stated objectives of the study-to inform public health policy and clinical practice in mental health settings-have been realized. It is important to remember that these decisions were made before the investigation started. In resolving 993 internal debates that informed these decisions during the design stage, the investigative team can reasonably be expected to defend its choices after the trial is over. If this anticipated defence has the potential to bias the debate on methodology, so too has the knowledge ofoutcomes available to critics after a study is complete. It is fair to say that knowing the MTA results has sharpened some of the concerns expressed later in this report. It is difficult, however, to quantify this bias, and we leave it for the reader to judge.
Large-Scale Trials-Objectives and Features
In the past 15 to 20 years, medicine has begun turning to large-scale trials as the means for evaluating the effectiveness of treating serious diseases in society ( 14) . Large-scale in this context can mean the random allocation of thousands of patients in dozens of clinical centres to different treatment arms (10) . The objective of randomizing so many patients and including so many settings is to provide reliable estimates of health outcomes applicable to a broad patient base treated under usual clinical conditions. Accordingly, these large-scale trials are concerned with effectiveness (the impact of treatment under usual clinical conditions) and not with efficacy (the impact of treatment under ideal conditions): they are intended to improve the management of important medical problems by demonstrating beyond reasonable doubt that a specific treatment is associated with moderate benefits without bias or chance. The public health value associated with modest, incremental improvements to treatment identified in large-scale trials comes with the broad applicability of the fmdings to practice settings and subsequent implementation of these treatments by informed clinicians and health care workers.
What are some ofthe basic features of large-scale trials? Peto and colleagues note that one ofthe fundamental requirements is a good question (10, p 336). Although no specific agreedupon criteria exist for good questions, they suggest that, "in general, the most important questions are those that assess the effects of some major outcome of various widely practicable treatments for a common disease" (original emphasis). A major outcome refers to relatively unambiguous endpoints-survival, disease remission-that are important to patients and are readily detectable. A widely practicable treatment is one that is easy for clinicians to implement and for patients to comply with. A common disease is one with high prevalence, afflicting a large segment of the population.
The elements of a good question described by Peto are intended to serve a shared feature oflarge-scale trials: simplicity. Unambiguous, readily detectable endpoints reduce error associated with misclassification and simplify data collection requirements, thus easing the burden ofparticipation on clinicians and patients. Practicable treatments increase the relevance and acceptability of interventions, simplify implementation and compliance, reduce burden on participants, and provide the basis for rapid dissemination and takeup should they prove effective. A common disease increases the public health salience of a treatment and ensures that treatments with reliable effects, moderate in size, will have substantial health benefits overall when used by clinicians to treat patients affected with the disease in question.
All clinical trials, regardless of scope, must be concerned with the control of systematic error or bias through representative subject enlistment, proper randomization, adherence to treatment protocols, accurate classification of outcomes, appropriate statistical analyses, and adequate power. The most important difference between large-scale and small-scale trials is the statistical power available in the former to detect reliable differences between treatment effects that are moderate in size and considered to be important clinically. Large-scale studies include large numbers ofpatients and clinical settings to take into account the real-world exigencies in effectiveness trials expected to attenuate treatment differences. Small-scale studies, in the search for large effects, must either test very powerful treatments or choose methods that maximize the opportunities for detecting large effects by minimizing the attenuating effects of unwanted variability.
MTA Study-A Review

Objectives
It is unclear from the available reports on the MTA study whether it should be viewed as a trial of effectiveness or efficacy. In the first paper to describe the background and rationale ofthe study, Richters and colleagues note that the decision to mount a multisite study was "to enhance the representativeness of the study and the generalizability of the fmdings"-a view consistent with an effectiveness trial (8, p 996). Hinshaw and colleagues draw attention to both the large-scale and multisite features of the MTA study, noting that "a key purpose of multisite trials is to generate data with broad generalizability and applicability to practice" (6, P 218). Later in this report, however, the authors discuss the development of subject inclusion and exclusion criteria as a function of achieving balance between internal and external validity. This discussion of sampling suggests that the investigators see the objectives ofefficacy (maximum control) and effectiveness (maximum generalizability) as needing to be reconciled in the study. Arnold and colleagues also capture this tension, discussing the "considerable challenges in designing a long-term clinical trial to be both scientifically valid and responsive to clinicians' needs" (4, p 869}-once again hinting that the basic study objective, to evaluate effectiveness or efficacy, is an unresolved issue. Finally, the recently published outcomes report uses the term "effectiveness" to designate the comparison of outcomes in the treatment arms but makes no attempt to characterize the study as a trial of effectiveness or efficacy (7).
Large-scale trials depend on the use of simple methods to address important questions about treatment effectiveness. This singular concern with the evaluation of effectiveness helps to focus the debate over appropriate methodology. Issues associated with sampling, measurement, treatment protocols, statistical analysis, and the control of error have a specific context for debate. Blurring the distinction between 994 The Canadian Journal of Psychiatry Vol 44, No 10 effectiveness and efficacy in a given study simply widens the room for debate about appropriate methodology. No useful context exists for selecting optimal methods, increasing the risk that some methodological decisions will favour one or the other objective with unclear consequences. Ambiguity in the overall objective of the MTA study sets the stage for contentious debate over some of the methodological decisions that have been made in the trial. The distinctive features ofefficacy and effectiveness studies focusing on child and adolescent psychotherapy have received attention elsewhere (15, 16) .
Research Questions
The In the outcomes report, the MTA study is represented by 3 questions: 1) Do medication and behavioural treatments result in comparable levels of improvement in pertinent outcomes at the end of treatment? 2) Do participants assigned to combined treatment show higher levels of improvement in overall functioning at the end of treatment in pertinent outcome domains than those assigned to either medication management or behavioural treatment? 3) Do participants assigned to each of the 3 MTA treatments show greater improvement over 14 months than those assigned to community care? (7) . Although these 3 questions constitute an advance in simplicity from the original manifold question, they still provide no guidelines for resolving differences of opinion on optimal methods for choosing endpoints, sampling, and specifying treatment. The problem here is simply an extension ofthe one associated with the MTA research objectives: the absence of a simple, concrete question removes the best context for choosing methods most likely to yield valid, relevant answers (17) .
Measurement
Peto and colleagues contend that "Most trials would be of much greater scientific value if they collected ten times less data, both at entry and during follow-up, and were therefore much larger" (10, P 336) . This speaks to the strategy recommended for large-scale trials to focus attention on 1 or 2 major outcomes associated with the disease in question-outcomes with high salience for the length or quality of life among affected individuals. Focusing on a small set of outcomes simplifies data measurement and collection, presumably increasing the quality of information collected and lessening the burden of participation.
The MTA investigators struggled with the trade-offs between their perceived needs for adequate measurement (that is, to assess multiple outcomes both categorically and dimensionally, in multiple settings, using multiple informants and methods; to assess treatment predictors, mediators, and moderators; and to assess service use) and their fear of exceeding the threshold ofrespondent burden, which could lead to poor-quality information and even attrition (6) . The approach to measurement and data collection in the MTA study is far from simple. It consisted of several phases encompassing intake, multiple screens, and the study proper. Phase A was a telephone screen; phase B was a mailed survey comprising rating scales for parents and teachers; phases C andD included clinic assessments and school observations. Baseline assessments (phase D) required about 11 hours from parents, 7 hours from children, and 1 hour from teachers. Assessments at 3,9,14, and 24 months varied slightly, requiring about 7.5 hours from parents, 7 hours from children, and1 hour from teachers.
The extent to which measurement and data collection protocols adversely affected the MTA is difficult to estimate. This could happen in several possible ways. 1) The burden of data collection could serve to exclude otherwise eligible families from participating in the trial: full participation in data collection was a condition of study enlistment.
2) The burden of completing self-administered questionnaires, participating in interviews, and being tested and observed could lead to careless, unreliable, and inaccurate responses. In our experience, the motivation, attention, and interest of respondents in general-population surveys starts to wane after about 90-120 minutes. 3) Measurement itself could serve as an intervention, affecting patterns of response from one occasion to the next. This would be a special problem if the impact of measurement varied by treatment arm and was conditioned by expectancies associated with a particular treatment. 4) Measurement demands could lead to sample attrition. Equal sample attrition across study arms would reduce statistical power (unless this was anticipated and additional subjects included at the outset) and could lead to bias if it was selective in 1 or more of the treatment arms.
Sample attrition overall in the MTA study was too small to be a factor, so the idea of measurement demands leading to selective sample loss at follow-up is inapplicable. The other concerns about measurement burden have yet to be addressed in the MTA study. Examining these measurement issues empirically would provide the field of child treatment research with important guidelines for future work. Measuring childhood psychopathology presents many difficult and complex problems that have conditioned investigators in general to develop inclusive measurement protocols without adequately knowing the implications for data quality. Also contributing to measurement burden in the MTA study was the desire to address multiple ancillary questions about effect modifiers and causal mechanisms. Although these are all interesting questions, they need not be packaged in 1 study, particularly ifattempts to address them compromise attainment ofthe primary objective.
Sampling
In large-scale trials, investigators attempt to include all patients with the disease in question, subject to "the uncertainty principle" (10) . The uncertainty principle states that randomization to treatment is reasonable as long as no basis exists for preferring one treatment over the other. In the presence ofuncertainty, Peto argues that restrictive criteria should be kept to a minimum so that patients entering the trial are as heterogeneous as possible. This recruitment strategy is based on the assumption that moderate treatment effects achieved in the sample as a whole are unlikely to be reversed in particular subgroups.
In the MTA study, the investigators set out to enlist a very heterogeneous sample: they "actively recruited girls," sought out children with "disparate comorbid diagnoses," and attempted to include "children and families either currently receiving treatment or who are amenable to intervention" (6) . The latter decision took sample recruitment beyond clinic referrals into the general population, where advertisements, word of mouth, and other methods were used to stimulate self-referral.
On one level, the enlistment strategies developed in the MTA study appear to be very inclusive: all children withADHD, irrespective of clinic status, would be eligible for study. The limiting factor behind this strategy is the lack of control over the factors determining self-selection. These factors or sample filters condition the identification and take-up of subjects and come in 2 forms: referral jilters, which control the movement of the subject pool toward the site, and study jilters, which control the enlistment and retention ofstudy subjects.
It is well known that referral filters can and do influence the findings arising from case-control and cohort studies carried out in clinical settings (18) . The usual method for reducing these effects is to focus on geographically defined areas, to ensure that all clinical sites in these areas are participants, and to recruit all eligible patients receiving care in these sites. Available reports provide no evidence that the MTA used this recruitment strategy. Rather than tighten control over recruitment, control was loosened, as noted above. Each MTA site was required to actively recruit and accept referrals from 4 sources: school settings; primary medical care; mental health practitioners and clinics; and self-referrals solicited by advertisements, parent self-help groups, and word ofmouth (6) . Although these strategies may yield a heterogeneous sample of ADHD children, selection factors may introduce unwanted biases that confound treatment effects. It is also possible that the accrued sample and its response in the trial may differ substantially from patients receiving treatment in clinical settings. The wisdom of recruiting study subjects outside of treatment facilities is debatable on the grounds that the clinical and administrative relevance of the sample may be jeopardized.
Study filters begin working when potential subjects are identified and screened for eligibility. The usual standard for determining eligibility comes from inclusion and exclusion criteria applied to clinically relevant data to ensure the inclusion of subjects with the condition of interest and the exclusion of subjects who may be placed at risk in the study or for whom a clear treatment preference exists. In the MTA, subjects meeting inclusion and exclusion criteria were also required to meet the practical requirements of being research participants. These practical requirements involved substantial investments from both the families and schools ofADHD children. For example, the screening process included 6 different encounters with families and dual assessment batteries in both clinic and school settings. Not only did families have to agree to randomization and participation in the treatment arm assigned to them, but schools (principals and teachers) had to comply with both assessment and intervention protocols to be implemented at school over the 24-month period of the trial. In the first 12 months of the study, 4 intensive data collection points included the use ofmultiple respondents and multiple methods ofassessment. Further, the treatment protocols demanded high levels of active participation, far beyond the expectations found in clinical settings.
The reporting of subject response in the MTA study makes it impossible to estimate accurately the impact ofdata treatment requirements on the recruitment of eligible subjects (7) . Among the 4541 screening calls taken in phase A, 579 subjects (12.8%) completed phase D and entered the trial. Summing across the 4 phases, there were 855 parent refusals and 454 miscellaneous losses that included school refusal. A recent ADHD treatment study by Schachar and colleagues serves as a comparison (19) . In this factorial trial to assess the effects of placebo medication versus methylphenidate crossed with parent management-training versus a self-help group, 135 of302 clinic referrals met eligibility criteria, and 91 (67%) were accepted and randomized.
Adhering to minimal data collection and treatment requirements in large-scale studies is meant to facilitate the enlistment oflarge numbers ofpatients and to achieve the objective of generalizability. In any treatment study, some research burden on participants is inevitable; however, the data collection and treatment protocols developed in the MTA study entail a substantial burden to a constellation ofpeople expected to participate in the study: parents, children, and teachers. What impact might these research requirements have on recruitment? First, eligible subjects with a clear preference for or against one treatment or another would have to be excluded. Available reports do not indicate the extent to which the perceptions of families about the relevance and utility of treatment options impacted on their study participation. This is very important information to obtain and disclose: it might indicate that child treatment studies should use different experimental designs; for example, ones that explicitly account for patient preferences (20) . Second, the research demands 996
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Do MTA study subjects represent families seeking help in child mental health settings? And are inferences about the average treatment response recorded in these subjects generalizable to a well-defined target population? These are difficult questions to answer, because only limited opportunities exist for comparing MTA subj ects with the proposed target population on relevant characteristics. Relevant characteristics are those variables most likely to influence subject course; they include both the clinical profile of child participants (for example, severity and duration of the targeted condition, comorbid disorders, and other functionalliabilities as well as strengths) and contextual forces within the home, neighbourhood, and school that have a bearing on outcome. The clinical data compiled within the MTA permits a comparison with other clinical and epidemiological profiles of ADHD children. However, it is not possible to compare contextual forces operating in the lives ofMTA participants, particularly aspects of subject motivation and expectancies, with similar characteristics at work among families attending clinics or found in community samples.
Treatment
Large-scale trials normally are designed to evaluate the effectiveness of practical treatments (10) . Practical treatments would be ones that are simple, inexpensive, easy to administer, generally acceptable to clinicians and patients, and pose relatively little burden. These treatments, ifshown to be moderately effective in large groups ofpatients, have the potential to be incorporated into clinical practice very quickly after study completion. Since large-scale studies focus on detecting important but moderate treatment effects, it is essential to minimize bias and random error. Accordingly, the impact of nonprotocol treatments administered either differentially or nondifferentially across treatment arms is an important consideration.
Treatment Complexity in the MTA Study. The treatments implemented in the MTA study were complex, demanding, and expensive. Even medication management offers several practical implementation challenges to clinicians working in child mental health centres. Consider the procedures to identify the optimal dosage for individual children (5). There was a 4-to l l-day lead-in phase designed 1) to help children overcome difficulties swallowing pills and 2) to identify major or prohibitive adverse effects associated with exposure to weightadjusted dosages of medication. This was followed by a 28-day double-blind, randomized titration trial. Stimulant doses were changed each weekday for 4 weeks. Parents and teachers provided behaviour ratings daily on symptoms, impairments, and side effects. The data from these ratings were graphed at the end of the 28-day trial, and these graphs were rated independently by clinicians to identify the "best-dose condition." Once medication began, there was a set of algorithms for managing medication decisions over the period of treatment.
It is even more difficult to envision disseminating the "package" ofbehavioural treatments used in the MTA. These treatments included parent training in home behavioural management, school-based intervention, and direct treatment of the child (7). The parent-training regimen involved 27 group and 8 individual sessions for each family over the study period. The school-based intervention involved teacher consultation in behavioural techniques over 10-16 sessions anda half-time, behaviourally-trained paraprofessional aide in the classroom for 12 weeks. Direct treatment ofthe child was delivered through an 8-week all-day summer treatment program.
Nonprotocol Treatment Use in the MTA Study. The outcomes report provides minimal information on the use of nonprotocol treatment in the MTA study (7) . The investigators noted that two-thirds of subjects assigned to community care received medication during the study period; they suggest that access to medication in this group accounted for the large net reduction in ADHD symptoms observed in that study arm, Details about this treatment, particularly its availability and use during data collection periods, were not provided.
In large-scale trials, the usual expectation is for nonprotocol treatment to be divided evenly across study arms so that bias is minimized. There are several reasons for expecting this: the use of randomization, the ability to conceal both subject allocation and treatment in pharmacological studies, acceptance of the uncertainty principal, and investigator control over the administration of treatment. Under these conditions, intentto-treat analyses of basic outcomes can be expected to yield unbiased estimates ofdifferential treatment effects. Although the MTA study included randomization and concealment of subject allocation, treatment status was common knowledge. More importantly, it appears that investigator control over treatment contamination (a patient in one study arm unintentionally given a study treatment meant only for another study arm) varied from one study arm to the next.
There are 2 obvious ways in which treatment contamination may have biased MTA outcome comparisons. 1) The procedures used with children assigned to community care triggered access to medication (as well as to other treatments). As the investigators noted, this was the most likely explanation for the pervasive use of medication reported in the community care group. The impact of this would be to improve outcomes in this group and to lessen in magnitude the relative effect sizes obtained in the other treatment arms. This bias toward the null was anticipated fully at the outset ofthe trial and justified on the grounds that deliberately withholding treatment from eligible subjects would be unethical.
2) Treatment contamination occurred more often among subjects allocated to medication management than to behavioural treatment. The argument for this is based on a series of December 1999 Lessons From Large Trials 997 assumptions. First, it is easier to control subject access to pharmacological interventions than to behavioural interventions, since the former require a prescription from a medical doctor. This additional control implies that children assigned to the behavioural-treatment group would have less opportunity of receiving medication than children assigned to the medication-management group would have of receiving a behavioural intervention. Second, it is assumed that study subjects in the medication-management group have ready access to "informal" behavioural interventions. Is this a reasonable assumption? It is not reasonable to assume that subjects in the medication-management group had ready access to the intensive behavioural regimens developed for the MTA study. It is reasonable to assume, however, that these subjects, indeed subjects in all of the treatment arms, had ready access to less intense behavioural interventions based more or less on principles similar to those underlying MTA behavioural treatment. Three mechanisms could account for this: 1) knowledge of subject enlistment, classification with ADHD, and treatment allocation (that is, to medication management) could stimulate parents, teachers, and others to search out behavioural assistance in addition to medication; 2) the availability to subjects in each of the 3 MTA treatment arms of a "bank" of 8 additional clinic sessions could have had unintended therapeutic effects or stimulated self-referral for behavioural help; and 3) the natural "diffusion" of behavioural interventions into books, videos, recreation centres, and classrooms could have exerted a positive effect on subjects. How would the exposure of all subjects to informal behavioural interventions impact on treatment effects? Presumably, it would improve outcomes in both the community care group and in the medication-management group relative to those receiving behavioural treatment and combined treatment. If the bias were large, it would be difficult to detect positive effects for behavioural treatment, either alone or in combination with stimulant medication.
MTA Effects-Methods and Treatment Studies in the Future
Has the MTA study produced valid and relevant estimates of effects for treatments that could be implemented in clinical practice? Most likely not, and for various reasons. 1) The treatments evaluated in the MTA study were both expensive and intensive, limiting the chances of them being implemented in clinical practice. This is a real-world limitation acknowledged by the investigators (7).
2) The absolute treatment effects obtained in the MTA study and measured in standard units were very high, from about 0.9 to 1.8. In our view, sample filters associated with the referral of subjects and burdensome requirements for participation limited enlistment to motivated families in supportive schools. These families were predisposed to benefit from treatment. This is far less likely among families referred to child mental health settings in the community. 3) Families assigned to medication management possibly had a greater opportunity to benefit from "informal" behavioural interventions than children assigned to behavioural treatment had to benefit from "informal" medication. If this is true, then the relative difference of effect between medication management and behavioural treatment would be misspecified, favouring better outcomes for medication management.
In this paper, the vision of trialists for large-scale treatment studies of cardiovascular disease and cancer provided the framework for discussing important elements of the MTA study. The relevance and usefulness of this framework depends somewhat on the extent to which the MTA meets criteria for the scope and intent of these studies. On the basis of sample size, it does not-large-scale studies in cardiovascular and cancer research often include thousands of patients. However, on the basis of other variables such as cost, expectancies for definitive findings, and purported relevance to clinical practice, it does lean toward large scale. To date, it is certainly the largest and most ambitious treatment trial of ADHD, and claims for its importance are unabashed: it is expected to set "an important benchmark for future trials testing new treatments for ADHD" (7).
In our view, large-scale studies of the effectiveness of treatments for child psychiatric disorders should be part of a comprehensive approach to understanding the usefulness of clinical interventions. This view is accompanied by a strong recommendation to consider the principles envisioned by trialists engaged in cardiovascular and cancer research. Studies should be aligned clearly with either effectiveness or efficacy objectives, but not both. Questions selected for study should be simple, clear, and important. Measurement, sampling, and data collection must adhere to the principle of simplicity to ensure maximum participation. All methodological decisions should be geared to attaining the research objectives: in effectiveness trials, this means evaluating treatments that have a high potential for dissemination if proven successful and recruiting only new referrals from child mental health settings.
Large and expensive studies are for good reason destined from their moment of conception to command a lot of attention. In the treatment of child disorder, this attention serves many helpful purposes: to highlight the needs of children, to provide information on the usefulness of treatment initiatives, and to stimulate debate on important issues, which will strengthen the empirical methods for obtaining relevant, high-quality information to guide clinical practice and health policy. The MTA study was a truly remarkable collaborative achievement, and it has raised the standard for technical excellence in child treatment research. It has also provided the energy to debate and resolve priorities for the design and implementation of future large-scale treatment studies concerned with the serious problem of childhood psychopathology.
